Category: Advancement
-
EF Hutton maintains price target on Enlivex after trial advancement By Investing.com
•
EF Hutton has affirmed its Buy rating on shares of Enlivex Therapeutics (NASDAQ: ), with a $13.00 price target. The firm’s stance comes in light of Enlivex’s recent announcement regarding the progress of its clinical trial for knee osteoarthritis. The Danish Medicines Agency has granted the company permission to start…
-
Germany’s Aleph Alpha is Europe’s best hope for developing AI advancement outside Silicon Valley
•
Only a handful of startups have been able to raise enough money to build and sustain powerful generative AI models. Germany’s Alev Alpha appears to be one of them. Late last year, the company announced a more than $500 million investment from the country’s industrial giants and one of its…